Sign inJoin waitlistJoin the waitlist

James Yao

, Professor, Department Chair · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
1998–2001
Internal Medicine
Baylor College of Medicine
1995–1998
Baylor College of Medicine
1991–1995

Research

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
Review · Journal of Clinical Oncology · 2008 · First of 11 authors · Corresponding · 3,501 citations
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
JAMA Oncology · 2017 · Last of 8 authors · 2,789 citations
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
New England Journal of Medicine · 2017 · 2,601 citations

Jaffer Ajani
43 papers
Daniel Halperin
40 papers · 8 as a fellow
Arvind Dasari
37 papers
Asif Rashid
36 papers
Matthew Kulke
31 papers
Alexandria Phan
27 papers
JS
Jonathan Strosberg
26 papers
Robert Wolff
18 papers
Ahmed Kaseb
17 papers
Jean-Nicolas Vauthey
15 papers
Edward Wolin
13 papers
Al Benson
12 papers

Grants

Texas EXperimental Cancer Therapeutics Network - TEX CTN
National Cancer Institute · UM1
PI · $20.4M · University of Tx Md Anderson Can Ctr
2014–2027
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma
National Cancer Institute · P50
Project lead · $996.7K · University of Tx Md Anderson Can Ctr
2019–2026
Phase I Studies of Targeted Anti-Cancer Therapies
National Cancer Institute · U01
Contact PI · $1.2M · University of Tx Md Anderson Can Ctr
1994–2015

Clinical trials

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2010
Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2008–2011
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
2007–2027
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2007–2014